In 2014, MAPS spun out a separate division to immediate study and put together for an eventual FDA software, which it submitted at the conclusion of final calendar year. In early 2024, that offshoot was renamed Lykos Therapeutics.Pseudohallucinations: it does not induce hallucinations for each se but produces illusions by altering the senses (all f